Aptamer Group PLC
LSE:APTA

Jigglypop Analysis For Aptamer Group PLC 🤓

Aptamer Group sits in speculative territory. At 0.95p, the shares are well off the 1.57p 52-week high yet quadruple the 0.231p low, underscoring high beta and momentum rather than deep value. Price now rides above the 50-day (0.90p) and 200-day (0.66p) averages after a 22.6% monthly burst, helped by reassuring runway guidance to June 2027 and fresh licensing deals with Twist and Alphazyme that bring upfronts, royalties and supply revenue. H1 revenue is guided to c.£0.83m, with a £3.1m pipeline and FY sales expected to top last year, but the market cap (~£25.6m) still bakes in execution risk. In short: improving story, credible partners, but the 52-week profile flags a momentum-led, speculative buy rather than a classic value play today.

About Aptamer Group PLC 👋

Aptamer Group PLC and its subsidiaries supply synthetic molecular binders for research, diagnostic, and therapeutic use across the United Kingdom, Europe, the United States, and worldwide. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers that bind to specific targets. The platform is applied in research reagents and analytics, bioprocessing, diagnostics, cosmetics and consumer health, and therapeutic settings. The company serves pharmaceutical, diagnostic, and bioprocessing customers. It collaborates with Unilever, Neuro-Bio, the University of Glasgow, AstraZeneca, and Invizius. Founded in 2008, Aptamer Group PLC is headquartered in York, United Kingdom.